Biologically targeted therapeutics in pediatric brain tumors

Pediatric Neurology

Volumn 46, Issue 4, 2012, Pages 203-211

  Nageswara Rao, Amulya A ^a,b,c   Scafidi, Joseph ^b,c   Wells, Elizabeth M ^b,c   Packer, Roger J ^b,c  

^a MAYO CLINIC   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CILENGITIDE; ENZASTAURIN; ERLOTINIB; GAMMA SECRETASE INHIBITOR; GEFITINIB; IMATINIB; LAPATINIB; LENALIDOMIDE; LONAFARNIB; MK 2206; NIMOTUZUMAB; PAZOPANIB; PROTEIN KINASE B INHIBITOR; PTC 299; RAPAMYCIN; RO 4929097; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VISMODEGIB;

ANTIANGIOGENIC ACTIVITY; ASTROCYTOMA; BRAIN TUMOR; CELL ADHESION; CHEMORADIOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; EPENDYMOMA; GLIOBLASTOMA; GLIOMA; HUMAN; MEDULLOBLASTOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PONTINE GLIOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SUBEPENDYMOMAL GIANT CELL ASTROCYTOMA;

ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; PEDIATRICS;

EID: 84859545351     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2012.02.005     Document Type: Review

References (111)

1. Central Brain Tumor Registry of the United States. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Hinsdale, IL: Central Brain Tumor Registry of the United States. Available at: www.cbtrus.org; 2011.
2. Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. JNCI 2009;101:946-58.
3. Turner CD, Rey-Casserly C, Liptak CC, Chordas C. Late effects of therapy for pediatric brain tumor survivors. J Child Neurol 2009;24:1455-63.
4. Warren KE, Packer RJ. Current approaches to CNS tumors in infants and very young children. Expert Rev Neurother 2004;4:681-90. (Pubitemid 38890596)
5. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: Biology, therapy, and late effects. Semin Radiat Oncol 2010;20:58-66.
6. Faury D, Nantel A, Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007;25:1196-208. (Pubitemid 46640565)
7. Lo HW. Targeting Ras-Raf-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 2010;10:840-8.
8. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R. Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neurol Oncol 2008;10:1040-60.
9. Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: A molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008;6:675-84.
10. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34.
11. Weiner HL. The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 1995;37:179-94.
12. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65. (Pubitemid 32467045)
13. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda) 2010;25:85-101.
14. Perona R. Cell signalling: Growth factors and tyrosine kinase receptors. Clin Transl Oncol 2006;8:77-82.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
16. Sun Y, Goderie SK, Temple S. Asymmetric distribution of EGFR receptor during mitosis generates diverse CNS progenitor cells. Neuron 2005;45:873-86. (Pubitemid 40395266)
17. Burgess AW. EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors 2008;26:263-74.
18. Bax DA, Gaspar N, Little SE, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 2009;15:5753-61.
19. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: Results from the Children's Cancer Group 945 cohort. J Neurosurg 2006;105(Suppl. 5):418-24. (Pubitemid 44954773)
20. Suri V, Das P, Pathak P, et al. Pediatric glioblastomas: A histopathological and molecular genetic study. Neurol Oncol 2009;11:274-80.
21. Nakamura M, Shimada K, Ishida E, et al. Molecular pathogenesis of pediatric astrocytic tumors. Neurol Oncol 2007;9:113-23. (Pubitemid 46580313)
22. Gilbertson RJ, Hill DA, Hernan R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003;9:3620-4. (Pubitemid 37169226)
23. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002;8:3054-64. (Pubitemid 35155014)
24. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80. (Pubitemid 27351746)
25. Gajjar A, Hernan R, Kocak M. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-93. (Pubitemid 41095029)
26. Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW. Antiepidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005;56:155-62. (Pubitemid 40054001)
27. Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: A study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium. J Clin Oncol 2009;27:5102-8.
28. Pillay V, Allaf L, Wilding AL, et al. The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009;11:448-58.
29. Jakacki RI, Hamilton M, Gilbertson RJ, et al. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: A Children's Oncology Group Phase I Consortium study. J Clin Oncol 2008;26:4921-7.
30. Geoerger B, Hargrave D, Thomas F, et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neurol Oncol 2011;13:109-18.
31. Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium. Neurol Oncol 2011;13:290-7.
32. Fouladi M, Stewart CF, Blaney SM, et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010;28:4221-7.
33. Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiother Oncol 2007;83:238-48. (Pubitemid 46915540)
34. Schaefer G, Shao L, Totpal K, Akita RW. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. Cancer Res 2007;67:1228-38.
35. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream ERK1/2 and Akt pathways. Oncogene 2002;21:6255-63.
36. Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011;11:247-56.
37. He Y, Cai W, Wang L, Chen P. A developmental study on the expression of PDGFalphaR immunoreactive cells in the brain of postnatal rats. Neurosci Res 2009;65:272-9.
38. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, et al. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 2006;51:187-99. (Pubitemid 44063617)
39. Ishii Y, Oya T, Zheng L, et al. Mouse brains deficient in neuronal PDGF receptor-b develop normally but are vulnerable to injury. J Neurochem 2006;98:588-600. (Pubitemid 44133161)
40. Shih AH, Holland EC. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2006;232:139-47. (Pubitemid 43170963)
41. Ostman A, Heldin CH. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007;97:247-74. (Pubitemid 46528991)
42. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010;28:1337-44.
43. Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010;28:3061-8.
44. Thorarinsdottir HK, Santi M, McCarter R, et al. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res 2008;14:3386-94.
45. Blom T, Roselli A, Häyry V, et al. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors. J Neurooncol 2010;97:217-24.
46. Baruchel S, Sharp JR, Bartels U, et al. A Canadian Paediatric Brain Tumour Consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer 2009;45:2352-9.
47. Geoerger B, Morland B, Ndiaye A, et al. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer 2009;45:2342-51.
48. Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report. Neurol Oncol 2007;9:145-60. (Pubitemid 46580316)
49. Bazzoni G. Signalling pathways and adhesion molecules as targets for antiangiogenesis therapy in tumors. Adv Exp Med Biol 2008;610:74-87.
50. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature 2005;438:954-9. (Pubitemid 43093961)
51. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue: Beyond blood vessels. Exp Neurol 2004;187:246-53. (Pubitemid 38610271)
52. Li Z, Bao S, Wu Q, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-13.
53. Jogi A, Øra I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002;99:7021-6. (Pubitemid 34526250)
54. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009;52:791-5.
55. Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neurol Oncol 2010;12:985-90.
56. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2010;28:3069-75.
57. Ma S, Rosen ST. Enzastaurin. Curr Opin Oncol 2007;19:590-5. (Pubitemid 47508866)
58. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)
59. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310. (Pubitemid 46763022)
60. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008;118:1739-49. (Pubitemid 351632377)
61. Kieran MW, Packer RJ, Onar A, et al. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2007;25:3137-43. (Pubitemid 47218063)
62. Fouladi M, Nicholson HS, Zhou T, et al. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: A Children's Oncology Group study. Cancer 2007;110:2535-41. (Pubitemid 350174941)
63. Haas-Kogan DA, Banerjee A, Poussaint TY, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neurol Oncol 2011;13:298-306.
64. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109. (Pubitemid 39331023)
65. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (Berl) 2011;121:397-405.
66. Gronych J, Korshunov A, Bageritz J, et al. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest 2011;121:1344-8.
67. Keir ST, Maris JM, Lock R, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010;55:1126-33.
68. Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008;51:42-8. (Pubitemid 351717388)
69. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62. (Pubitemid 43128863)
70. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010;55:668-77.
71. Cheng CK, Fan QW, Weiss WA. PI3K signaling in glioma: Animal models and therapeutic challenges. Brain Pathol 2009;19:112-20.
72. Pollack IF, Hamilton RL, Burger PC, et al. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: A report from the Children's Oncology Group. J Neurooncol 2010;99:155-63.
73. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30. (Pubitemid 44050136)
74. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-9. (Pubitemid 43668732)
75. Baryawno N, Sveinbjörnsson B, Eksborg S, Chen CS, Kogner P, Johnsen JI. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res 2010;70:266-76.
76. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11.
77. Huber H, Eggert A, Janss AJ, et al. Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 2001;37:2064-72. (Pubitemid 32938110)
78. Sie M, de Bont ES, Scherpen FJ, Hoving EW, den Dunnen WF. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma: Is it much different from glioblastoma? Neuropathol Appl Neurobiol 2010;36:636-47.
79. Herrington B, Kieran MW. Small molecule inhibitors in children with malignant gliomas. Pediatr Blood Cancer 2009;53:312-7.
80. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-15. (Pubitemid 30106600)
81. Turner CD, Chi S, Marcus KJ, et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol 2007;82:95-101.
82. Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium Study PBTC-018. J Clin Oncol 2011;29:324-9.
83. Becchetti A, Arcangeli A. Integrins and ion channels in cell migration: Implications for neuronal development, wound healing and metastatic spread. Adv Exp Med Biol 2010;674:107-23.
84. Streuli CH, Akhtar N. Signal co-operation between integrins and other receptor systems. Biochem J 2009;418:491-506.
85. Teodorczyk M, Martin-Villalba A. Sensing invasion: Cell surface receptors driving spreading of glioblastoma. J Cell Physiol 2010;222:1-10.
86. Abdollahi A, Griggs DW, Zieher H, et al. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11:6270-9. (Pubitemid 41262958)
87. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Invest Drugs 2008;17:1225-35.
88. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:2712-8.
89. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 2008;26:919-24. (Pubitemid 351398085)
90. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24:1924-31. (Pubitemid 46638992)
91. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: Clinicopathological correlates of SHh, Wnt, and non-SHh/Wnt molecular subgroups. Acta Neuropathol (Berl) 2011;121:381-96.
92. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the SHh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-) p53(-/-) mice. Cancer Cell 2004;6:229-40. (Pubitemid 39222036)
93. Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: Insights from mouse mutants. Nat Neurosci 2005;8:709-15. (Pubitemid 43085834)
94. Ables JL, Breunig JJ, Eisch AJ, Rakic P. Not(ch) just development: Notch signalling in the adult brain. Nat Rev Neurosci 2011;12:269-83.
95. Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005;65:2353-63. (Pubitemid 40490146)
96. Shih IM, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82.
97. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009;107:600-8.
98. Furchert SE, Lanvers-Kaminsky C, Juurgens H, et al. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007;120:1787-94. (Pubitemid 46399367)
99. Spiller SE, Ditzler SH, Pullar BJ, Olson JM. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008;87:133-41.
100. Yin D, Ong JM, Hu J, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 2007;13:1045-52. (Pubitemid 46340384)
101. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: A Children's Oncology Group phase I consortium report. J Clin Oncol 2010;28:3623-9.
102. Wolff JE, Kramm C, Kortmann RD, et al. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 2008;90:309-14.
103. Su JM, Li XN, Thompson P, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: A Children's Oncology Group report. Clin Cancer Res 2011;17:589-97.
104. Masoudi A, Elopre M, Amini E, et al. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 2008;28:2437-42.
105. Graham C, Tucker C, Creech J, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 2006;12:223-34. (Pubitemid 43166198)
106. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010;28:4390-9.
107. Zhu Z, Shen Z. Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol Ther 2011;12:3.
108. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol 2008;88:245-50.
109. Curtin JF, King GD, Candolfi M, et al. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem 2005;5:1151-70. (Pubitemid 41644889)
110. Parsa A, Han CCS, Kivett V, et al. Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): Results of a phase II multicenter clinical trial with immunological assessments. J Clin Oncol 2011;29(Suppl.):2565.
111. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6.